Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Trilaciclib + Sacituzumab Govitecan-hziy in Triple Negative Breast Cancer Patients

A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting

Disease Types: Breast

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting

For More Information:

https://clinicaltrials.gov/ct2/show/NCT05113966?term=Trilaciclib+in+triple+negative+breast+cancer&draw=2&rank=2